Brief: ALK's Acarizax Meets Main Goal In China Late-Stage Allergy Trial
Mon 14:34
BRIEF-ALK's Acarizax Meets Main Goal In China Late-Stage Allergy Trial Oct 19 (Reuters) - ALK-Abello A/S ALKb.CO:
REG-PHASE 3 TRIAL IN CHINA SUCCESSFULLY CONFIRMS ACARIZAX® SAFETY AND EFFICACY IN PATIENTS WITH HOUSE DUST MITE ALLERGY
PHASE 3 TRIAL WITH ACARIZAX IN CHINA MEETS PRIMARY OBJECTIVE AFTER 24-28 WEEKS
ACARIZAX SHOWN TO BE SAFE AND WELL-TOLERATED IN CHINESE PHASE 3 TRIAL
ALK AND GENSCI TO FILE FOR ACARIZAX REGULATORY APPROVAL IN CHINA IN H1 2027
TRIAL RESULTS DO NOT AFFECT ALK'S FINANCIAL GUIDANCE FOR 2026
Source text: ID:nGNE511FwF
Further company coverage: [ALKb.CO]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))